MA56043A - Dérivés hétérocycliques fusionnés - Google Patents

Dérivés hétérocycliques fusionnés

Info

Publication number
MA56043A
MA56043A MA056043A MA56043A MA56043A MA 56043 A MA56043 A MA 56043A MA 056043 A MA056043 A MA 056043A MA 56043 A MA56043 A MA 56043A MA 56043 A MA56043 A MA 56043A
Authority
MA
Morocco
Prior art keywords
fused heterocyclic
heterocyclic derivatives
derivatives
fused
heterocyclic
Prior art date
Application number
MA056043A
Other languages
English (en)
Inventor
Jan Martin Berke
Zhanling Cheng
Gang Deng
Lindsey Graham Deratt
Sandrine Céline Grosse
Lili Hu
Yimin Jiang
Tim Hugo Maria Jonckers
Bart Rudolf Romanie Kesteleyn
Scott D Kuduk
Morgan Charles R Lecomte
Lamenca Carolina Martinez
Serge Maria Aloysius Pieters
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Wim Gaston Verschueren
Yanping Xu
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA56043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA56043A publication Critical patent/MA56043A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA056043A 2019-05-28 2020-05-27 Dérivés hétérocycliques fusionnés MA56043A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933 2019-05-28
CN2020085720 2020-04-20

Publications (1)

Publication Number Publication Date
MA56043A true MA56043A (fr) 2022-04-06

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056043A MA56043A (fr) 2019-05-28 2020-05-27 Dérivés hétérocycliques fusionnés

Country Status (19)

Country Link
EP (1) EP3976617B1 (fr)
JP (1) JP2022535734A (fr)
KR (1) KR20220012913A (fr)
CN (1) CN113906028A (fr)
AU (1) AU2020285718A1 (fr)
BR (1) BR112021022889A8 (fr)
CA (1) CA3138168A1 (fr)
CL (1) CL2021003155A1 (fr)
CO (1) CO2021016433A2 (fr)
CR (1) CR20210666A (fr)
DO (1) DOP2021000230A (fr)
IL (1) IL288322A (fr)
JO (1) JOP20210313A1 (fr)
MA (1) MA56043A (fr)
MX (1) MX2021014575A (fr)
PE (1) PE20220767A1 (fr)
PH (1) PH12021552974A1 (fr)
SG (1) SG11202113167QA (fr)
WO (1) WO2020243135A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022116999A1 (fr) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Dérivés hétérocycliques fusionnés et leur utilisation dans le traitement d'une infection par le vhb
AR124222A1 (es) * 2020-12-02 2023-03-01 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
WO2022116998A1 (fr) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Dérivés hétérocycliques fusionnés utilisés en tant qu'inhibiteurs du vhb
US20240279227A1 (en) * 2021-06-02 2024-08-22 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
AR126049A1 (es) 2021-06-02 2023-09-06 Janssen Sciences Ireland Unlimited Co Derivados heterocíclicos condensados
WO2024114709A1 (fr) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company Forme cristalline d'un composé dérivé d'hétérocycle fusionné
WO2024140851A1 (fr) * 2022-12-28 2024-07-04 上海维申医药有限公司 Inhibiteur de récepteur de type toll, sa préparation et son application

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (fr) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Dérivés de pyrazolopyridine et leur utilisation en thérapie
WO2016109684A2 (fr) * 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Dérivés et méthodes de traitement d'infections provoquées par le virus de l'hépatite b
AU2017290755B2 (en) * 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
EP3478692B1 (fr) * 2016-06-29 2020-06-17 Novira Therapeutics Inc. Dérivés d'oxadiazepinone et leur utilisation pour le traitement des infections hepatites b
BR112021021564A2 (pt) * 2019-04-30 2022-01-04 Aicuris Gmbh & Co Kg Indol-2-carboxamidas inovadoras ativas contra o vírus da hepatite b (hbv)

Also Published As

Publication number Publication date
DOP2021000230A (es) 2022-05-31
BR112021022889A2 (pt) 2022-01-04
CL2021003155A1 (es) 2022-07-22
WO2020243135A1 (fr) 2020-12-03
SG11202113167QA (en) 2021-12-30
CA3138168A1 (fr) 2020-12-03
PH12021552974A1 (en) 2022-07-11
IL288322A (en) 2022-01-01
JP2022535734A (ja) 2022-08-10
CN113906028A (zh) 2022-01-07
KR20220012913A (ko) 2022-02-04
JOP20210313A1 (ar) 2021-11-25
BR112021022889A8 (pt) 2024-03-05
PE20220767A1 (es) 2022-05-16
MX2021014575A (es) 2022-05-24
CR20210666A (es) 2022-03-11
CO2021016433A2 (es) 2021-12-10
EP3976617B1 (fr) 2025-04-23
EP3976617A1 (fr) 2022-04-06
AU2020285718A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
IL283333A (en) New heterocyclic compounds
PT3958977T (pt) Derivados de camptotecina
IL292161A (en) New methylquinazolinone derivatives
MA56043A (fr) Dérivés hétérocycliques fusionnés
EP4013751C0 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
LT3830085T (lt) Deuterinti lanifibranoro dariniai
IL279977A (en) Anthelminthic heterocyclic compounds
EP4061813C0 (fr) Dérivés de pyrrolidine
EP4077334C0 (fr) Dérivés furoindazole
EP4021904C0 (fr) Dérivés d'alpha-d-galactopyranoside
DK3768669T3 (da) Piperazinazaspiroderivater
EP4010076C0 (fr) Dérivés (hétéro)aryl-méthyl-thio-bêta-d-galactopyranoside
PL4301748T3 (pl) Triazolilo-metylo podstawione pochodne alfa-d-galaktopiranozydu
ZA202106024B (en) Heterocyclic derivatives
EP3884940A4 (fr) Nouveau dérivé d'imidazole
DK3898637T3 (da) Rapamycin-derivater
PL3921307T3 (pl) Pochodne pirazolu
DK3823970T3 (da) Yderligere substituerede triazoloquinoxalinderivater
EP3813522C0 (fr) Modèles de tauopathie
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
IL304774A (en) Enhanced sophorolipid derivatives
EP3822270A4 (fr) Nouveau dérivé hétérocyclique
DK3782986T3 (da) Heterocyklisk forbindelse
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK4396183T3 (da) Substituerede s-alaninatderivater